Immunovia nabs CMS preliminary payment determination

2022 07 08 16 10 0843 Research Money 400

Immunovia on Monday said the U.S. Department of Health and Human Services’ Centers for Medicare and Medicaid Services (CMS) has issued a preliminary payment determination for the firm’s Immray PanCan-d test.

The CMS preliminary payment determination implied a test price of $897.

The price determination agrees with a recommendation by the Clinical Diagnostic Laboratory Tests (CDLT) Advisory Panel to crosswalk the Immray PanCan-d rate to code 81503, brand name OVA1, which currently has a price of $897, Immunovia said.

"While this does not represent a coverage determination to reimburse the Immray PanCan-d test,

it is an important step in the process of securing reimbursement for the Immray PanCan-d test in the early detection of pancreatic cancer," Philipp Mathieu, CEO and president of Immunovia, said in a statement.

Immray PanCan-d is a blood test launched as a laboratory-developed test in August 2021 for the early detection of pancreatic cancer.

The Lund, Sweden-based company said it expects CMS to finalize its basis for the payment decision in November.

Page 1 of 8
Next Page